Therapix Biosciences LTD. – American Depositary SH (NASDAQ:TRPX) Sellers Strengthened By 88.5% Their Shorts

June 27, 2018 - By Lena Young

Change of 88.5% for Therapix Biosciences LTD. – American Depositary SH (NASDAQ:TRPX)’s shares shorted was noted. It was issued in June by FINRA the 183,600 shares shorted on TRPX. The 97,400 previous shares are up with 88.5%. Therapix Biosciences LTD. – American Depositary SH (NASDAQ:TRPX) has 39,000 shares average volume. It’ll cost 5 days for TRPX to restore its previous position. Float short on Therapix Biosciences LTD. – American Depositary SH is 6.39%.

TRPX reached $4.18 during the last trading session after $0.25 change.Therapix Biosciences Ltd. has volume of 55,138 shares. Since June 27, 2017 TRPX has declined 32.12% and is downtrending. TRPX underperformed by 44.69% the S&P 500.

Therapix Biosciences Ltd., a specialty clinical-stage pharmaceutical company, develops drugs based on cannabinoid molecules.The company has $14.82 million market cap. The Company’s drug development programs include Joint Pharma that develops THX-TS01 for the treatment of Tourette Syndrome ; and BrainBright Pharma, which develops THX-ULD01, a drug candidate based on an ultra-low dose of dronabinol for the treatment for mild cognitive impairment.Last it reported negative earnings. Therapix Biosciences Ltd. has a product development agreement with Cure Pharmaceutical to develop cannabinoid product for sleep disorders.

For more Therapix Biosciences Ltd. (NASDAQ:TRPX) news released briefly go to: Benzinga.com, Prnewswire.com, Gurufocus.com, Benzinga.com or Streetinsider.com. The titles are as follows: “Benzinga’s Daily Biotech Pulse: vTv Swoons On Failed Alzheimer’s Trial, Regenxbio Gets FDA Fast Track For RGX-111” released on June 13, 2018, “Cannabis’ Economic Impact to Expand With Emerging Markets” on June 14, 2018, “Therapix Biosciences Updates Regarding TASE Delisting” with a publish date: June 27, 2018, “Therapix Biosciences Announces Enrollment of the First Patient for Clinical Trial at Assuta Medical Center for Treating …” and the last “Form S-1 Intiva BioPharma Inc.” with publication date: June 07, 2018.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.